Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

GlobeNewswire January 18, 2023

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development

GlobeNewswire November 30, 2022

AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

GlobeNewswire November 23, 2022

AC Immune to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 8, 2022

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire October 28, 2022

AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer's Disease and Down Syndrome

GlobeNewswire October 4, 2022

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease

GlobeNewswire September 26, 2022

AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson's Disease Diagnostic Imaging Agent

GlobeNewswire September 1, 2022

AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer's and Parkinson's Diseases

GlobeNewswire August 24, 2022

AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer's and Parkinson's Diseases

GlobeNewswire August 11, 2022

Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC

GlobeNewswire August 2, 2022

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire July 28, 2022

AC Immune Announces Upcoming Presentations at the Alzheimer's Association International Conference

GlobeNewswire July 22, 2022

AC Immune Holds Annual General Meeting of Shareholders

GlobeNewswire June 24, 2022

AC Immune Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer's Disease

GlobeNewswire June 16, 2022

AC Immune to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire May 31, 2022

AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award

GlobeNewswire May 17, 2022

AC Immune's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

GlobeNewswire May 9, 2022

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire April 28, 2022

AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

GlobeNewswire April 27, 2022